PATENT CLAIM ANALYSIS

Application Number: 16199739
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-07
Patent Classification: ["514", "259300"]

Abstract:
A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.

Claim (Index 7):
The liquid formulation of  claim 6 , wherein the base comprises at least one of sodium citrate monohydrate, potassium citrate monohydrate, calcium citrate monohydrate, sodium citrate dihydrate, potassium citrate dihydrate, calcium citrate dihydrate, sodium citrate trihydrate, potassium citrate trihydrate, calcium citrate trihydrate, sodium citrate tetrahydrate, potassium citrate tetrahydrate, calcium citrate tetrahydrate, sodium citrate pentahydrate, potassium citrate pentahydrate, calcium citrate pentahydrate, sodium citrate hexahydrate, potassium citrate hexahydrate, calcium citrate hexahydrate, sodium citrate heptahydrate, potassium citrate heptahydrate, or calcium citrate heptahydrate.

Metadata:
- Claim Count in Document: 40.0
- Percentile: 98.0
- Lexical Diversity: 1.4878
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15622544', '15622388', '15861017', '15872769', '15399207']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7176353802396838
- 35 USC 102 Novelty (BERT): 0.6088936111911907
- Combined Prediction Score: 0.7067612033348344
- Mean Citation Score: 449.37463400000007
- Max Citation Score: 551.3446
- Similarity Product: 460.6535080699563

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test